NEW YORK, June 09, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Intra-Cellular Therapies, Inc. securities (NASDAQ:ITCI) from August 12, 2014 through April 28, 2017, inclusive (the “Class Period”) of the important July 11, 2017 lead plaintiff deadline in the first filed class action commenced by Rosen Law Firm. The lawsuit seeks to recover damages for Intra-Cellular Therapies investors under the federal securities laws.
To join the Intra-Cellular Therapies class action, go to http://www.rosenlegal.com/cases-1111.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) as a result, Intra-Cellular Therapies’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1111.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


OpenAI Addresses Security Vulnerability in macOS App Certification Process
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 



